Market Research Logo

Raynauds Disease - Pipeline Review, H2 2015

Raynauds Disease - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Raynauds Disease - Pipeline Review, H2 2015’, provides an overview of the Raynauds Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Raynauds Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Raynauds Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Raynauds Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Raynauds Disease Overview
Therapeutics Development
Pipeline Products for Raynauds Disease - Overview
Pipeline Products for Raynauds Disease - Comparative Analysis
Raynauds Disease - Therapeutics under Development by Companies
Raynauds Disease - Therapeutics under Investigation by Universities/Institutes
Raynauds Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Raynauds Disease - Products under Development by Companies
Raynauds Disease - Products under Investigation by Universities/Institutes
Raynauds Disease - Companies Involved in Therapeutics Development
Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Human Stem Cells Institute
Raynauds Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alprostadil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ELS-140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
neovasculgen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
riociguat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Alpha 2 Adrenergic Receptor for Raynauds Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Raynauds Disease - Recent Pipeline Updates
Raynauds Disease - Dormant Projects
Raynauds Disease - Discontinued Products
Raynauds Disease - Product Development Milestones
Featured News & Press Releases
Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference
Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May
Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Raynauds Disease, H2 2015
Number of Products under Development for Raynauds Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Raynauds Disease - Pipeline by Allergan Plc, H2 2015
Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H2 2015
Raynauds Disease - Pipeline by Bayer AG, H2 2015
Raynauds Disease - Pipeline by Human Stem Cells Institute, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Raynauds Disease Therapeutics - Recent Pipeline Updates, H2 2015
Raynauds Disease - Dormant Projects, H2 2015
Raynauds Disease - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Raynauds Disease, H2 2015
Number of Products under Development for Raynauds Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report